【作者】 程楚； 何波； 赵波涛；

【Author】 Cheng Chu He Bo Zhao Bo-Tao Dept of Med one, Jiangxi cancer Hosp. No.519 East Beijing Rd, Donghu Distr, Nanchang .330029 Jiangxi, PR China

【机构】 江西省肿瘤医院；

【摘要】 目的:探讨拓朴异构梅抑制剂．AT1258联合治疗紫杉类、蒽环类耐药转移性晚期乳腺癌的疗效及不良反应。方法:采用伊立替康(CPT-11)180mg／m2第1天或羟基喜树碱(HCPT)10mg静滴第1～5天,AT1258 40mg／m2 第1～5天,每三周为一周期。结果:全组共19例,CR3例, PR8例,SD5例,PD3例,总有效率达57．8％。主要不良反应是中性粒细胞减少,Ⅲ、Ⅳ度发生率52．6％。结论:拓朴异构梅抑制剂CPT-11或羟基喜树碱．AT1258无交叉耐药, 具有协同作用。两种药物联合化疗,对紫杉类、蒽环类、异长春碱(NV B)耐药转移性晚期乳腺癌取得较好疗效。更多还原

【Abstract】 Objective: To observe the efficacy and adverse reactions of topoisomerase inhibitor combined with AT1258 in the treatment of advenced breast cancer. Methods: Nineteen Patients with locally advanced or metastatic breast cancer were received treatment. The schedule is consisted of CPT-11 180mg/m2 d1, or HCPT 10mg day 1-5, and AT 1258 40mg/m2 d1-5. Treatment was repeated every 21 days up to a maximum of three cycles Results : CR 3 patients ,PR 8 patients NC 5 patients ,PD 3 patients .Objective responses were observed in 11 of 19 patients (57.8%). The main adverse reaction is neutro-penia , with 52.6% of patients affected at ID or IV. Conclusion: Topoisomerase inhibitor CPT-11or HCPT did not change drug resistance with AT 1258 and cooperation. This schedule achieves good levels of response. It is suitable for patients who were failure from the treatment of doxorubicin or docetaxel.更多还原